Serum mianserin and ageing
Progress in Neuro-Psychopharmacology and Biological Psychiatry, ISSN: 0278-5846, Vol: 18, Issue: 5, Page: 833-845
1994
- 10Citations
- 8Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations10
- Citation Indexes10
- 10
- CrossRef8
- Captures8
- Readers8
- Mentions1
- References1
- 1
Article Description
1.1. Mianserin is a tetracyclic antidepressant with relatively few anticholinergic and cardiovascular sideeffects. Its clinical efficacy is comparable to that of tricyclic antidepressants. It is widely used in Europe, especially in elderly outpatients.2.2. In the present studies, the authors have evaluated the efficacy of mianserin as well as the effects of ageing and concomitant psychotropic drugs on serum mianserin concentrations in 169 depressive psychiatric inpatients.3.3. In the patients the mean serum mianserin concentrations or their interindividual variations did not differ between the old, middle-aged, and young age groups. Furthermore, elderly women and men did not differ from each other for their dose-related drug concentrations. Neither were any differences found in serum mianserin concentrations between the older (≥75 years) and younger elderly (65–74). As is the case with TCAs, the co-administration of neuroleptics increased serum mianserin concentrations in the elderly. When comparing the therapeutic response and serum mianserin concentrations the authors found that the patients with good clinical improvement had higher mean serum mianserin concentrations than those without efficacy.4.4. There seem to be no clinically important changes in the phannacokinetics of mianserin with advancing age. The present results do not support the claim that the therapeutic profile of this drug is altered with advancing age. Mianserin can be regarded as an antidepressant with relatively few side-effects in the elderly.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/0278584694901007; http://dx.doi.org/10.1016/0278-5846(94)90100-7; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0027932508&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/7972855; https://linkinghub.elsevier.com/retrieve/pii/0278584694901007; http://dx.doi.org/10.1016/0278-5846%2894%2990100-7; https://dx.doi.org/10.1016/0278-5846%2894%2990100-7
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know